Three large US drug distributors and drugmaker Johnson & Johnson will proceed with a proposed $26bn settlement resolving claims that they fuelled the opioid epidemic after “enough” states joined in, the companies said.
The companies had until Saturday to decide whether enough states back the $21bn proposed settlement with McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, and a $5bn agreement with J&J.
Keep readinglist of 3 items
The distributors said on Saturday 42 states, five territories and Washington, DC, signed on to their agreement. The exact tally for J&J’s related deal was not immediately clear.
The companies will make their first annual settlement payment into escrow on or before September 30, the distributors said. The final amount will depend on several factors, including the final participation rate of states and political subdivisions, they added.
North Carolina Attorney General Josh Stein, a lead settlement negotiator, called the support level a “remarkable showing of unity and commitment across the country to address this problem”.
The settlement’s complex formula envisioned at least 44 states participating, but ultimately the companies got to decide whether a “critical mass” had joined and whether to finalise the deal.
A number of states had previously said they had not fully signed on by an August 21 deadline: Alabama, Georgia, Nevada, New Mexico, Oklahoma, Washington, and West Virginia.
Cities and counties within participating states have through January 2 to join, as well. Ultimately, $10.7bn is tied to the extent localities participate.
The deal, unveiled by 14 state attorneys general on July 21, is designed to resolve more than 3,000 lawsuits accusing the distributors of ignoring red flags that pain pills were being diverted into communities for illicit uses and that J&J played down the risks of opioid addiction.
The money would fund treatment and other services.
The companies deny wrongdoing, saying the drugs were approved by the US Food and Drug Administration and that responsibility for ballooning painkiller sales lies with doctors, regulators and others.
The deal is separate from a settlement resolving similar claims against OxyContin maker Purdue Pharma LP and its wealthy Sackler family owners. A bankruptcy judge on Wednesday approved that deal, which Purdue values at more than $10bn.